OBP-301 (a telomerase-specific, replication-competent adenovirus with hTERT promoter) was constructed in a previous study and it showed a strong anticancer effect by inducing cell lysis in human lung and prostate cancer cells. This study investigated the effectiveness of a combination therapy of OBP-301 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was confirmed in vitro in the RENCA cancer cells. In in vivo experiment, luciferase-expressing RENCA cells were implanted in the left kidney and lung of BALB/c mice to prepare the RCC metastatic model. The animals were randomly divided into four treatment groups: PBS, IL-2 alone, OBP-301 alone and the combination. The analyses of orthotopic tumor weight, lung metastasis and luciferin-stained tumor images 14 days after each treatment showed significant tumor growth inhibition in the combination group in comparison with that in the OBP-301-or IL-2-treated groups. In addition, the percentage of regulatory T-cells (Tregs) in the combination group was significantly suppressed in comparison with that in the PBS and single-agent treatment groups. The outcomes of this study suggest that tumor-specific oncolytic immunovirotherapy may become an attractive strategy for the treatment of human RCC.
Introduction
Renal cell carcinoma (RCC) has become the fourth most common genitourinary cancer, with more than 51 000 new cases and about 13 000 cancer-specific deaths recorded per year in the United States. 1 A considerable number of patients show distant metastasis at the time of diagnosis. Despite undergoing surgical treatment, chemotherapy and radiotherapy, most of the RCC patients show disease progression and metastasis. Therefore, there is an urgent need for developing novel and effective therapies for RCC.
Telomerase is a ribonucleoprotein complex responsible for complete replication of chromosome ends, and its activation is considered to have a crucial role not only in cell proliferation but also carcinogenesis. [2] [3] [4] [5] Previous studies have showed enhanced telomerase activity in more than 85% of human cancers, but only in a few normal somatic cells. 3, 4 Human telomerase reverse transcriptase (hTERT) positively regulates telomerase activity at the transcriptional level and is selectively overexpressed in proliferating neoplastic tissues and cells. [2] [3] [4] [5] Therefore, it seems reasonable to consider the hTERT promoter as a cancer-specific promoter. Previous study developed a unique strategy for oncolytic virotherapy based on the replicative capacity of the adenovirus by placing the envelope-1 (E1) gene under the control of an hTERT promoter. [6] [7] [8] [9] [10] OBP-301 (telomelysin), a cancer-selective, replication-competent oncolytic adenovirus, can induce cell lysis in human non-small-cell lung cancer and prostate cancer cells. 6, 9 OBP-301 has the ability to replicate within tumors, enter the blood circulation and then replicate in distant metastatic tumors after the intratumoral administration. 9 Interleukin-2 (IL-2) is a member of the immunocytokine family and was approved by Food and Drug Administration (FDA) of the United States for treatment of metastatic RCC. 11 However, the overall response rates of immunotherapy have been shown to be 6.5%. 12 Due to the limited efficacy of IL-2 treatment, an effective treatment strategy that includes a combination of other methods is required for increasing the efficacy of IL-2 immunotherapy. This study investigated whether a combination therapy of OBP-301 and IL-2 has enhanced antitumor and antimetastatic effects in a mouse model of orthotopic RCC in comparison with OBP-301 or IL-2 therapy alone.
Materials and methods

Animals
Female BALB/c mice (6-8 weeks old) were purchased from SLC (Hamamatsu, Japan). They were maintained in a specific pathogen-free environment with free access to food and water at the laboratory animal center of Okayama University. They were allowed to adapt to their environment for more than 1 week before beginning the experiments. The animals were housed and handled in accordance with the Okayama University Animal Research Committee Guidelines.
Cell line
The mouse RCC cell line (RENCA) was provided by the American Type Culture Collection (Rockville, MD). The RENCA cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum. The cells were cultured at 37 1C in a 5% CO 2 atmosphere and routinely passaged by trypsin-EDTA treatment in 100-cm 2 flasks.
OBP-301 and recombinant IL-2 protein OBP-301 (telomelysin, a tumor-specific, replication-competent adenovirus) is a construct in which the hTERT promoter drives the expression of the E1A and E1B genes linked with an internal ribosome entry site. 6, 7 Before use, these viruses were purified by CsCl 2 step-gradient followed by CsCl 2 linear-gradient ultracentrifugation. Recombinant human IL-2 protein was kindly provided by Shionogi Co. (Osaka, Japan), and this protein was diluted in the culture medium just before use for the in vitro studies, and in phosphate-buffered saline (PBS) for the in vivo studies.
In vitro cell number assay RENCA cancer cells were seeded onto a 96-well plate at a density of 1000 cells per well. After 24 h of incubation, the cells were treated with OBP-301 added at a multiplicity of infection (MOI) of 0.1, 1 and 10, or with recombinant IL-2 protein at 10, 100 and 1000 U ml
À1
. Furthermore, RENCA cells were treated with 1 MOI of OBP-301 mixed with 10, 100 and 1000 U ml À1 IL-2. The in vitro cell-killing effect was analyzed by determining the cell number at the indicated time points using a cell proliferation kit containing sodium 3 0 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate assay (Roche Diagnostics, Indianapolis, IN), according to the manufacturer's instructions.
Imaging of RCC tumors in mouse
The tumors derived from luciferase stably transfected RENCA cells were imaged by the luciferase expression in the tumors. Briefly, the animals were anesthetized with isoflurane before and during imaging, and then were injected intraperitoneally with luciferin (a substrate for luciferase) at 150 mg kg À1 in a volume of 100 ml. The animals were imaged at a peak time of 20 min after luciferin injection using an IVIS-200 instrument (Xenogen, Alameda, CA), using exposure times and sensitivity settings to avoid saturation. Images were processed using the Living Image software program (Xenogen), by means of a region-of-interest analysis of the total photons per second for each tumor, with appropriate background subtraction. Potent antitumor effects of OBP-301 and IL-2 combined therapy P Huang et al (in 100 ml PBS) were intravenously injected through the tail vein. At 10 days after cell injection, tumor imaging was performed and mice were divided into four treatment groups (namely, PBS, IL-2, OBP-301 and the combination (OBP-301 plus IL-2)) according to tumor burden. The mice were administered 16 000 U of recombinant IL-2 protein intraperitoneally or/and with OBP-301 (10 7 plaque forming units/100 ml) through the tail vein, on day 0, day 2 and day 4 of the treatment. In the PBS treatment group, 100 ml of PBS was injected both intraperitoneally and intravenously as the vehicle control. On day 14 after each treatment, tumor imaging was performed and tumor volume was analyzed in each mouse. The mice were then killed and the weight of the orthotopic tumor in the left kidney and the bilateral lung tissue specimens with metastases were measured.
Flow cytometry
For flow cytometry, 100 ml of blood sample from each mouse was collected in a plastic tube containing EDTA.
The blood was then incubated with phycoerythrin-labeled anti-mouse CD4 antibody (eBioscience, San Diego, CA) and fluorescein isothiocyanate-labeled anti-mouse Foxp3 antibody (eBioscience) for 1 h at 4 1C. The labeled sample was washed twice with cold PBS. The sample was resuspended in 250 ml of cold PBS and analyzed using a fluorescence-activated cell sorter (FACS) Calibur flow cytometer (BD Biosciences, San Jose, CA) by gating on lymphocytes.
13
Histology and immunohistochemistry The mice were killed for histological analysis on day 14 after each treatment. The tissues were removed, fixed in formalin, embedded in paraffin and sectioned. Sections measuring 5 mm were stained with hematoxylin and eosin, and examined for histological changes. Immunohistochemistry was performed using a primary antibody against adenovirus type-5 E1A (BD PharMingen, San Diego, CA) to identify the OBP-301-infected tumor cells, as previously described. 14, 15 Briefly, the tumor tissue was excised, placed in the optimal cutting temperature compound and snap-frozen in liquid nitrogen. The frozen sections (10 mm) were fixed in 4% paraformaldehyde in PBS for 30 min at room temperature, washed and Potent antitumor effects of OBP-301 and IL-2 combined therapy P Huang et al permeabilized with PBS containing 0.1% Triton X-100. Endogenous peroxidase activity was blocked by incubating the sections in 3% hydrogen peroxide in methanol for 10 min. The sections were incubated with the primary antibody (1:50 dilution with PBS) at room temperature for 16 h and then with Histofine Simple Stain MAX PO (Nichirei, Tokyo, Japan) for 30 min. Subsequently, bound antibodies were detected using diaminobenzidine-tetrahydrochloride as the substrate and the sections were then counterstained with hematoxylin.
Statistical analysis
The data are shown as the mean ± s.d. Unpaired Student's t-test was performed for analyzing the statistical difference between any two groups. Differences were considered to be significant if the P-value was less than 0.05.
Results
In vitro anticancer efficacy of OBP-301 and IL-2 in RENCA cells
The RENCA cells were infected with OBP-301 at the indicated MOIs to determine whether OBP-301 infection induces cancer cell-killing. At an MOI of 10, a significant reduction in RENCA cell number to less than 20% was observed on day 3 and day 4 after OBP-301 treatment (Figure 1a ). Increasing concentrations of recombinant IL-2 protein (10-1000 U ml À1 ) did not contribute any antiproliferative effects on RENCA cells (Figure 1b) . When RENCA cells were treated with 1 MOI of OBP-301 mixed with 10, 100 and 1000 U ml À1 of IL-2, the addition of IL-2 did not enhance the cell-killing effect of OBP-301 (data not shown).
Potent antitumor effects of combined OBP-301 and IL-2 treatment on both orthotopic and metastatic tumors in the RCC mouse model The therapeutic efficacy of OBP-301 plus IL-2 treatment on the growth of RENCA cells was assessed in vivo. Luciferase-expressing RENCA cells were injected orthotopically and intravenously into immunocompetent mice to produce a mouse RCC model with an orthotopic tumor and metastatic lung tumors. Ten days after the cell injection, tumor luciferase signaling was typically observed in the area of left kidney (Figure 2a , Before treatment (Day 0)) using the IVIS instrument. Next, the mice were subjected with one of four treatments (PBS, IL-2, OBP-301 and the combination (OBP-301 plus Potent antitumor effects of OBP-301 and IL-2 combined therapy P Huang et al IL-2)). After 14 days of the treatment, PBS-treated mice showed significant tumor growth, as estimated by the IVIS instrument (Figure 2 ). OBP-301 administration induced more than 50% reduction of tumor growth in comparison with that in the PBS group (Figure 2b) . The combination of OBP-301 and IL-2 protein induced a potent tumor-inhibitory effect that was statistically strong in comparison with that induced by administration of each single agent. The tissue weight of the orthotopic tumor 14 days after the treatment revealed that the combination treatment induced a significant inhibition of the tumor growth in the kidney (Figure 3a) . The growth of metastatic lung tumors was also assessed in the treatment groups. After 14 days of treatment, bilateral lungs were removed and weight was measured. The PBS-treated group showed a large number of lung tumors on the surface (Figure 3b) . The increase of the lung weight was significantly suppressed in the OBP-301 and IL-2 combination group in comparison with that in the other groups, thus indicating the strongest inhibitory effects of the lung tumor growth (Figure 3b) . The tissue weight of orthotopic tumor and lungs with metastatic tumor was correlated with the level of luciferase expression analyzed by the IVIS instrument between the treatment groups.
In vivo synergistic effect of OBP-301 treatment on the downregulation of peripheral CD4 þ Foxp3 þ Tregs by IL-2 administration The population of CD4 þ Foxp3 þ regulatory T-cells (Tregs) is elevated in patients with progressive cancer and Tregs can thwart protective antitumor immunity. [16] [17] [18] Recent human cancer trials suggest that depleting Tregs can be clinically beneficial. 16, 18 To explore the potential mechanisms underlying the potent antitumor effect elicited by the combination of OBP-301 and IL-2, the percentage of the CD4 þ 
Discussion
Oncolytic adenoviruses have been developed as a novel antitumor therapeutic strategy and their effectiveness is being currently tested in clinical trials. 9 To improve the therapeutic index of anticancer agents, it is necessary that they selectively target cancer cells and spare normal cells. Investigators have been focusing on developing such cancer-specific biochemical drugs. 8, 13 A replication-selective, tumor-specific adenoviral agent, OBP-301, was constructed for development of a cancer-specific therapeutic modality. OBP-301 has potent anticancer activities against many types of human malignancies such as lung, colon and prostate cancer. 6, 9 The in vitro assay with mouse RCC cells showed the cytotoxic effect of OBP-301. Conversely, no cytotoxic effect was induced by IL-2 treatment alone. It is reasonable because IL-2 will not be able to exert its Potent antitumor effects of OBP-301 and IL-2 combined therapy P Huang et al anticancer effects in the absence of immune cells. In the in vivo experiment, intravenously administrated OBP-301 had significant cancer-killing effects in the both orthotopic renal tumor and in metastatic lung tumors. There was no definite histological damage in the examined normal organs. In addition, immunohistochemical examination disclosed the definite cancer selectivity because adenoviral E1A expression was clearly observed in the tumor tissue but not in normal tissue. These results indicate that intravenously injected OBP-301 can specifically target the cancer tissue in the kidney and lung through the blood vessel and can replicate in the tumor.
This study showed that combined administration of intravenous OBP-301 and intraperitoneal IL-2 induced robust therapeutic effects on both orthotopic renal tumor and on metastatic lung tumors. To examine anticancer immunomodulation in each mouse, the ratio of peripheral CD4 þ Foxp3 þ Tregs was measured by FACS analysis. Although there was no inhibitory effect of the Treg cell population after treatment with OBP-301 alone, the population of Tregs was significantly downregulated after the combined OBP-301 plus IL-2 therapy in comparison with that in the group treated with IL-2 alone. Therefore, the in vivo synergistic effect of OBP-301 treatment on the IL-2-induced downregulation of peripheral Tregs was observed in the current RCC model. This immunological synergistic effect on the suppression of Tregs may explain the robust antitumor therapeutic effects exerted by the OBP-301 plus IL-2 combination therapy.
IL-2 is a T-cell growth factor that is thought to have a crucial role in the regulation of T-cell-dependent immune responses. High-affinity IL-2-receptor-mediated cell signaling is crucial for regulation of Tregs in vivo. 18 Therefore, it appears that the therapeutic effect of IL-2 is at least partially due to the immunological activation induced by the downregulated Treg lymphocytes. In addition, a recent study showed that OBP-301 virusmediated oncolysis might be an effective stimulus for immature dendritic cells to induce specific response against cancer cells in humans. 10 These findings may provide the clue to clarify the mechanism of synergistic antitumor immunological response elicited by the combination of OBP-301 and IL-2.
In conclusion, the combined administration of OBP-301 and IL-2 exhibited a potent therapeutic effect in the model of RCC without any definite toxicity. These findings are noteworthy in terms of the clinical applications of this combination therapy for patients with both primary and metastatic RCC. The outcomes of this study also provide important implications regarding replication-selective oncolytic immunovirotherapy in human cancers.
